S. Yamazaki et al., Lack of interaction between bropirimine and 5-fluorouracil on human dihydropyrimidine dehydrogenase, XENOBIOTICA, 31(1), 2001, pp. 25-31
1. Bropirimine (2-amino-5-bromo-6-phenyl-6-pyrimidinone) is a member of a c
lass of antineoplastic agents that are administered concomitantly or sequen
tially with anticancer 5-fluorouracil (5-FU) prodrugs in clinical patients.
Interactions between bropirimine and 5-fluorouracil (5-FU) were investigat
ed on dihydropyrimidine dehydrogenase (DPD) activity, the rate-limiting enz
yme of 5-FU metabolism, in human liver cytosol. Apparent DPD activity was d
etermined by measuring the recovery of [C-14]5-FU by HPLC.
2. The apparent activity of 5-FT metabolism (2.1-100 muM) showed alinear re
lationship in the Eadie-Hofstee plot in the pooled cytosol, suggesting that
a single enzyme is responsible for apparent 5-FU metabolism. K-m and V-max
were estimated to be 23 muM and 0.32 nmol min(-1) mg(-1) protein, respecti
vely. Apparent DPD activity for 5-FU (25 muM) in the cytosol from 12 indivi
dual donors ranged from 0.017 to 0.39 (0.16+/-0.12) nmol min(-1) mg(-1) pro
tein, indicating a large intersubject variance.
3. The suicidal inactivators of the DPD enzyme, (E)-5-(2-bromovinyl)uracil
and 5-bromouracil (6.3-50 muM), illustrated concentration-dependent inhibit
ion on DPD activity. Isocytosine (6.3-100 muM), used as a negative control,
did not affect DPD activity. Bropirimine (6.3-100 muM) also did not show a
ny inhibition of DPD activity. Therefore, bropirimine is unlikely to cause
increases in 5-FU levels in clinical patients after co-administration of br
opirimine with 5-FU prodrugs.